FDA Brief

Warning letters Drugs

FDA warning letter to

Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center, LLC

High riskIssued Oct 21, 2022Posted Nov 1, 2022Office of Pharmaceutical Quality Operations, Division II

FDA warned Nephron Sterile Compounding Center about insanitary sterile drug production and sterility assurance failures found in a 2022 inspection.

What happened

FDA inspected the West Columbia, SC outsourcing facility from March 28 to April 20, 2022, and issued a Form FDA 483. Investigators found about 1,686 microbial contamination excursions in the ISO 5 aseptic processing area without adequate corrective action or product evaluation, and media fills that did not simulate the largest batch size. The company later recalled some sterile drug products because of a lack of sterility assurance.

What FDA found

  1. The facility did not take adequate corrective action or evaluate product impact after about 1,686 microbial contamination excursions in the ISO 5 aseptic processing area.

    FDCA section 501(a)(2)(A)
  2. Media fills were not performed under the most challenging conditions, such as simulating the largest batch size, so there was no assurance of aseptic production.

    FDCA section 501(a)(2)(A)
  3. The firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

    21 CFR 211.42(c)(10)(iv)
  4. The firm failed to conduct appropriate laboratory testing for each batch, as necessary, to be free of objectionable microorganisms.

    21 CFR 211.165(b)
  5. The firm failed to thoroughly investigate unexplained discrepancies or failures of a batch or its components to meet specifications.

    21 CFR 211.192
  6. The firm compounded drug products using glycopyrrolate bulk drug substance that was not on the 503B bulks list and was not used for a drug on the shortage list.

    FDCA section 503B(a)(2)(A)

What FDA wants

FDA tells Nephron to notify the office in writing within 15 working days of the specific steps taken to address the violations, with explanations, supporting documentation, and any reason for delay.

Who should pay attention

  • hospitals and clinics that buy compounded sterile drugs
  • pharmacies or brands that source from this outsourcing facility
  • quality teams at other 503B outsourcing facilities

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk
  4. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk